HIV News and Research

RSS

AiCure closes $12.25 million in Series A fundraising round

AiCure, an artificial intelligence company connecting the world's patients to better treatments and improved health, has closed a Series A fundraising round with $12.25 million. The consortium is led by New Leaf Venture Partners, with additional participation from Pritzker Group Venture Capital, Tribeca Venture Partners, and Biomatics Capital, established by Boris Nikolic, former Chief Advisor for Science and Technology to Bill Gates.

11 Jan 2016

New study finds significant racial disparity in patients with HIV and Hodgkin lymphoma

A new study finds a significant racial disparity within a doubly troubled population of patients: those with HIV and Hodgkin lymphoma. In such cases, blacks are at significantly higher risk than whites of not receiving treatment for the cancer that in many cases would be effective.

11 Jan 2016

Patient recommendations for rheumatoid arthritis treatment: an interview with Dr Nowell

The study, “When patients write the guidelines: Patient panel recommendations for the treatment of RA,” published in Arthritis Research & Care, demonstrated the feasibility of developing CPG recommendations based on a voting panel composed entirely of patients.

8 Jan 2016

ISHLT issues new list of criteria to determine patient eligibility for heart transplant

To determine patient eligibility for heart transplant, the International Society for Heart Lung Transplantation maintains a list of criteria, first issued in 2006, that acts as a guideline for physicians.

7 Jan 2016

Transgender veterans have significantly greater prevalence of many psychiatric and medical conditions

The first large, controlled study of health disparities between clinically diagnosed transgender and non-transgender patients-based on the medical records of more than 5,000 patients treated in the Veterans Health Administration-showed that transgender veterans had a significantly greater prevalence of numerous psychiatric and medical conditions.

7 Jan 2016

Modeling research shows adding a vaccine to HIV/AIDS response necessary to conclusively end the epidemic

Adding a vaccine to the comprehensive HIV/AIDS response is essential to conclusively ending the epidemic, according to modeling research published today.

6 Jan 2016

Nearly 7 in 10 middle and high school students exposed to e-cigarette ads

About 7 in 10 middle and high school students – more than 18 million young people – see e-cigarette advertising in stores, online, in newspapers and magazines, or on television and in movies, according to a new CDC Vital Signs report.

6 Jan 2016

Mylan announces U.S. launch of generic Ortho Tri-Cyclen Lo Tablets

Mylan N.V. today announced the U.S. launch of Norgestimate and Ethinyl Estradiol Tablets USP, 0.18 mg/0.025 mg, 0.215 mg/0.025 mg, and 0.25 mg/0.025 mg, which is the generic version of Janssen's Ortho Tri-Cyclen Lo Tablets.

5 Jan 2016

International panel of clinical experts comment on state of their fields

In an Editorial published this week in PLOS Medicine, editors ask an international panel of eleven expert researchers and clinicians spanning a range of specialties to answer questions on their field and what developments they hope and expect to see in 2016.

30 Dec 2015

Mylan announces launch of Linezolid Tablets, 600 mg in U.S.

Mylan N.V. today announced the U.S. launch of Linezolid Tablets, 600 mg, which is the generic version of Pfizer's Zyvox Tablets. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for this product, which is indicated in adults and children for the treatment of certain infections caused by susceptible Gram-positive bacteria.

29 Dec 2015

Ebola virus and bats waging molecular battle for survival

Ebola virus and bats have been waging a molecular battle for survival that may have started at least 25 million years ago, according to a study led by researchers at Albert Einstein College of Medicine, the University of Colorado-Boulder (CU-Boulder) and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) that published online today in the journal eLife.

24 Dec 2015

Single VRC01 antibody infusion could suppress HIV level in people not taking ART

A single infusion of a powerful antibody called VRC01 can suppress the level of HIV in the blood of infected people who are not taking antiretroviral therapy (ART), scientists at the National Institutes of Health report in a paper published today.

24 Dec 2015

Immunogeneticist helps monitor immune responses in VRC01 phase 1 trial in HIV-infected individuals

Janardan Pandey, Ph.D., an immunogeneticist specializing in immunoglobulin GM genes at the Medical University of South Carolina, helped monitor for immune responses that could limit the effectiveness of the broadly neutralizing antibody VRC01 in a phase 1 trial of that antibody in HIV-infected individuals led by a team at the Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

24 Dec 2015

Medication poisoning threatens young children in poor areas

Children younger than 5 who live in economically disadvantaged areas had a greater risk of medication poisoning that resulted in referral to a health care facility, according to scientists at the University of Pittsburgh Graduate School of Public Health and the University of California, San Diego. These areas were rural and experienced high unemployment, along with lower rates of high school graduation and lower household income.

23 Dec 2015

New footage shows how AIDS vaccine candidate recruits immune cells to destroy infected cells

Using innovative technology, scientists from the Institut Pasteur and Inserm have filmed in vivo the process by which an AIDS vaccine candidate, developed by the French Vaccine Research Institute and the ANRS, triggers the immune response.

23 Dec 2015

ATS commends President Obama for release of National Action Plan to combat TB

The American Thoracic Society applauds President Barack Obama and the Administration for the release of the National Action Plan to Combat Drug Resistant Tuberculosis (TB) today.

23 Dec 2015

Baxalta announces initial results from ADYNOVATE Phase 3 trial for treatment of hemophilia patients

Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, today announced initial results from a Phase 3 clinical trial of ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended circulating half-life recombinant Factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)].

22 Dec 2015

FDA updates blood donor deferral recommendations to help ensure continued safety of blood supply

Today, the U.S. Food and Drug Administration issued final guidance outlining updated blood donor deferral recommendations to reflect the most current scientific evidence and to help ensure continued safety of the blood supply by reducing the risk of human immunodeficiency virus (HIV) transmission by blood and blood products.

22 Dec 2015

Roche announces availability of cobas HBVassay for use on cobas 4800 System

Roche announced today the commercial availability of the cobas HBVassay for use on the cobas 4800 System in countries accepting the CE mark. This new molecular diagnostic assay expands the available virology menu on the cobas 4800 System, improving system efficiency and providing testing flexibility that allows physicians to assess a patient's response to antiviral therapy.

22 Dec 2015

Targeted alpha therapy has potential to reduce HIV-infected cells from central nervous system

Targeted alpha therapy has the potential to selectively eliminate HIV infected cells from the central nervous system, according to a recent study co-authored by the JRC. The study shows that a specific human antibody labelled with the alpha emitter bismuth-213 can penetrate the blood brain barrier and selectively target and destroy HIV-infected cells while sparing non-infected healthy cells.

21 Dec 2015

HIV News and Research

AiCure closes $12.25 million in Series A fundraising round

New study finds significant racial disparity in patients with HIV and Hodgkin lymphoma

Patient recommendations for rheumatoid arthritis treatment: an interview with Dr Nowell

ISHLT issues new list of criteria to determine patient eligibility for heart transplant

Transgender veterans have significantly greater prevalence of many psychiatric and medical conditions

Modeling research shows adding a vaccine to HIV/AIDS response necessary to conclusively end the epidemic

Nearly 7 in 10 middle and high school students exposed to e-cigarette ads

Mylan announces U.S. launch of generic Ortho Tri-Cyclen Lo Tablets

International panel of clinical experts comment on state of their fields

Mylan announces launch of Linezolid Tablets, 600 mg in U.S.

Ebola virus and bats waging molecular battle for survival

Single VRC01 antibody infusion could suppress HIV level in people not taking ART

Immunogeneticist helps monitor immune responses in VRC01 phase 1 trial in HIV-infected individuals

Medication poisoning threatens young children in poor areas

New footage shows how AIDS vaccine candidate recruits immune cells to destroy infected cells

ATS commends President Obama for release of National Action Plan to combat TB

Baxalta announces initial results from ADYNOVATE Phase 3 trial for treatment of hemophilia patients

FDA updates blood donor deferral recommendations to help ensure continued safety of blood supply

Roche announces availability of cobas HBVassay for use on cobas 4800 System

Targeted alpha therapy has potential to reduce HIV-infected cells from central nervous system

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Exploring the G:Box and for high-quality imaging

Latest News